🧾 What This Document Is — Your Company Playbook for the Annual Vote

This is a DEF 14A, also known as a Proxy Statement. Think of it as a detailed invitation and guidebook for Edgewise Therapeutics' shareholders. Its main job is to give you all the information you need to vote on important company decisions before the Annual Meeting on June 4, 2026.

👉 In simple terms: The company is asking its owners (shareholders) to vote on three key items: who should be on the board, who should audit the books, and whether they approve of the top executives' pay packages.

🏢 What The Company Does — A Mission to Fix Muscle Diseases

Edgewise Therapeutics is a late-stage clinical biopharmaceutical company. They discover and develop new drugs for severe muscle diseases with high unmet needs, like muscular dystrophies and heart conditions.

👉 Their core strategy is to use a unique platform that targets the muscle as an organ, creating small molecule drugs (pills) that can regulate key proteins. Their lead programs are in Becker muscular dystrophy and hypertrophic cardiomyopathy (a heart muscle disease).

🗳️ The Three Big Votes at the Annual Meeting

Shareholders are being asked to decide on these proposals. The board recommends voting FOR all of them.

1. Proposal 1: Elect Three Directors You're voting to elect Laura Brege, Badreddin Edris, Ph.D., and Jonathan Root, M.D. to the board. They will serve until 2029. Each brings unique experience from biotech, venture capital, and finance.

2. Proposal 2: Ratify the Auditors You're asked to confirm KPMG LLP as the company's independent accounting firm for 2026. This is a standard "check-in" to ensure shareholders agree with the auditor choice.

3. Proposal 3: Advisory Vote on Executive Pay ("Say-on-Pay") This is a non-binding vote where shareholders can express their opinion on the compensation paid to top executives like the CEO, CFO, and other named officers. The board will consider the results when making future pay decisions.

👥 Board & Governance — Who's Running the Show?

The board is split into three classes. This election is for Class II directors. Here are the nominees up for election:

Laura Brege (68): Senior Advisor at BridgeBio Pharma. Brings deep biotech board and finance experience. Audit Chair & Compensation Committee member.
Badreddin Edris, Ph.D. (39): Co-founder of Edgewise, now President & COO of Beeline Medicines. Offers an operator's and venture capital perspective. Compensation Committee Chair.
Jonathan Root, M.D. (66): General Partner at U.S. Venture Partners. Provides medical and VC investment expertise. Nominating & Corporate Governance Chair & Audit Committee member.

Other Key Board Members:

Peter Thompson, M.D. (66): Board Chair & Co-founder (Partner at OrbiMed).
Kevin Koch, Ph.D. (65): President & CEO (Director).
Alan Russell, Ph.D. (56): Co-founder & Chief Scientific Officer (Director).

👉 Governance Highlight: The company has a policy that prohibits hedging and pledging of company stock by insiders. It also has a Compensation Recovery Policy ("clawback") to reclaim executive pay if financial results are later restated.

💼 Executive Compensation — How the Top Team is Paid

Here’s a snapshot of the 2025 pay structure for the named executive officers, which includes the CEO, CFO, and other top leaders.

Base Salary: The CEO's base salary was $670,000. Other executive salaries ranged from about $466,000 to $530,000.
Annual Bonus: The target bonus is a percentage of base salary (e.g., 60% for the CEO). For 2025, the board determined the company achieved its goals at 115%, leading to higher payouts.
Long-Term Incentives: The primary form of compensation is stock options and Restricted Stock Units (RSUs). These vest over four years, aligning executive interests with long-term shareholder value.
- Example: In August 2025, executives received new grants of options and RSUs that vest monthly or annually over four years.

👉 What This Signals: The compensation philosophy is heavily weighted towards long-term, equity-based awards to retain talent and drive multi-year performance, which is typical for a clinical-stage biotech.

💸 Financial Position & The Company's Story

While this isn't a financial results filing, the proxy provides important context:

The company is in a late-stage clinical phase, meaning it's focused on expensive final trials before potential drug launches.
Its first commercial launch is planned for Becker muscular dystrophy. The recent addition of a director with commercial launch experience (Christopher Martin) underscores this upcoming milestone.
The focus is on advancing two key programs: sevasemten (for muscular dystrophies) and EDG-7500 (for heart disease).

🔮 What's Next — Strategic Roadmap

The company's strategy focuses on:

Preparing for its first commercial launch in Becker muscular dystrophy.
Advancing its cardiovascular drug EDG-7500 into Phase 3 trials.
Expanding its drug discovery platform for more muscle diseases.
Exploring strategic collaborations to accelerate development.

⚖️ Big Picture — Strengths & Risks

👍 Strengths: Focused expertise in muscle biology, late-stage pipeline with promising data, strong insider and institutional backing, and a board with deep biotech and commercial experience.
⚠️ Risks: As a clinical-stage biotech, its success hinges on drug trial results and regulatory approvals. Any failure or delay in its lead programs could significantly impact the company. The upcoming commercial launch is also a major execution challenge.

🧠 The Analogy — Building a Specialized Race Car

Think of Edgewise as a team building a highly specialized, high-performance race car (their drugs) to compete in a very specific race (treating severe muscle diseases). This proxy statement is a look under the hood before the big race:

You're voting on which expert mechanics should be on the pit crew (the board).
You're approving the inspector who checks the car's specs (the auditor).
You're reviewing how the star driver is being paid (executive comp). The company has the car in the final stages of tuning (late-stage trials) and is getting ready for its first major competition (product launch).

🧩 Final Takeaway

This proxy is your chance, as a shareholder, to help steer Edgewise Therapeutics as it transitions from a research-focused biotech to a company on the verge of its first product launch. Your votes will help shape the governance and leadership overseeing this critical, high-risk, high-reward phase of the company's journey.

EWTX shares proxy details annual votes for directors and compensation